KpperFCCarpenterLJMcFiggansGBPalmerCJWaiteTJBonebergEMet al
Indications: Tardive dyskinesia tardive dyskinesia is a neurological disorder characterized by involuntary movements believed to be caused by dopamine hypersensitivity, and which is associated with the long-term use of antipsychotic drugs that antagonize dopamine receptors
It is indicated for the treatment of adult patients with R/R LBCL after two or more lines of systemic therapy, including DLBCL, HGBCL, and PMBCL ( Abecma, the first anti-BCMA CAR-T product, was approved on March 26, 2021, and is indicated for treating adult patients with R/R MM after immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies targeting CD38 ( Carvykti, a bi-epitope nanobody-based anti-BCMA CAR-T product, was approved on February 28, 2022, for adults with R/R MM after four or more prior lines of therapy, including IMiDs, PIs, and an anti-CD38 monoclonal antibody ( Aucatzyla, a CD19-directed CAR-T therapy, received approval on November 8, 2024, for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
However, individual responses to any medication can vary
M., Hong, S
Liposomal delivery wraps the glutathione in a protective fatty layer, allowing it to bypass digestion and enter your cells directly
